{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T20:12:16Z","timestamp":1649016736034},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,9,29]],"date-time":"2014-09-29T00:00:00Z","timestamp":1411948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2014,9,29]],"date-time":"2014-09-29T00:00:00Z","timestamp":1411948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1038\/bmt.2014.210","type":"journal-article","created":{"date-parts":[[2014,9,29]],"date-time":"2014-09-29T14:56:54Z","timestamp":1412002614000},"page":"139-141","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Sclerodermatous chronic GVHD in patients receiving tyrosine kinase inhibitors after allogeneic hematopoietic cell transplantation"],"prefix":"10.1038","volume":"50","author":[{"given":"A","family":"Salhotra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S H","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Paris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Parker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S J","family":"Forman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,9,29]]},"reference":[{"key":"BFbmt2014210_CR1","doi-asserted-by":"publisher","first-page":": 14","DOI":"10.1056\/NEJM199907013410103","volume":"341","author":"G Socie","year":"1999","unstructured":"Socie G, Stone JV, Wingard JR, Weisdorf D, Henslee-Downey PJ, Bredeson C et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med 1999; 341 : 14\u201321.","journal-title":"N Engl J Med"},{"key":"BFbmt2014210_CR2","doi-asserted-by":"publisher","first-page":": 703","DOI":"10.7326\/0003-4819-87-6-703","volume":"87","author":"AA Gratwohl","year":"1977","unstructured":"Gratwohl AA, Moutsopoulos HM, Chused TM, Akizuki M, Wolf RO, Sweet JB et al. Sjogren-type syndrome after allogeneic bone-marrow transplantation. Ann Intern Med 1977; 87 : 703\u2013706.","journal-title":"Ann Intern Med"},{"key":"BFbmt2014210_CR3","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/art.22314","volume":"56","author":"JH Distler","year":"2007","unstructured":"Distler JH, Jungel A, Huber LC, Schulze-Horsel U, Zwerina J, Gay RE et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007; 56: 311\u2013322.","journal-title":"Arthritis Rheum"},{"key":"BFbmt2014210_CR4","doi-asserted-by":"publisher","first-page":": 719","DOI":"10.1182\/blood-2009-02-204750","volume":"114","author":"L Magro","year":"2009","unstructured":"Magro L, Mohty M, Catteau B, Coiteux V, Chevallier P, Terriou L et al. Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease. Blood 2009; 114 : 719\u2013722.","journal-title":"Blood"},{"key":"BFbmt2014210_CR5","doi-asserted-by":"publisher","first-page":": 4070","DOI":"10.1182\/blood-2011-03-341693","volume":"118","author":"GL Chen","year":"2011","unstructured":"Chen GL, Arai S, Flowers ME, Otani JM, Qiu J, Cheng EC et al. A phase 1 study of imatinib for corticosteroid-dependent\/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies. Blood 2011; 118 : 4070\u20134078.","journal-title":"Blood"},{"key":"BFbmt2014210_CR6","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.bbmt.2011.10.042","volume":"18","author":"I Sanchez-Ortega","year":"2012","unstructured":"Sanchez-Ortega I, Servitje O, Arnan M, Orti G, Peralta T, Manresa F et al. Dasatinib as salvage therapy for steroid refractory and imatinib resistant or intolerant sclerotic chronic graft-versus-host disease. Biol Blood Marrow Transplant 2012; 18: 318\u2013323.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2014210_CR7","doi-asserted-by":"publisher","first-page":"4111","DOI":"10.1182\/blood-2013-05-494278","volume":"122","author":"A Olivieri","year":"2013","unstructured":"Olivieri A, Cimminiello M, Corradini P, Mordini N, Fedele R, Selleri C et al. Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD. Blood 2013; 122: 4111\u20134118.","journal-title":"Blood"},{"key":"BFbmt2014210_CR8","doi-asserted-by":"publisher","first-page":"5098","DOI":"10.1182\/blood-2012-10-464198","volume":"121","author":"Y Inamoto","year":"2013","unstructured":"Inamoto Y, Storer BE, Petersdorf EW, Nelson JL, Lee SJ, Carpenter PA et al. Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease. Blood 2013; 121: 5098\u20135103.","journal-title":"Blood"},{"key":"BFbmt2014210_CR9","first-page":"258","volume":"91","author":"C Skert","year":"2006","unstructured":"Skert C, Patriarca F, Sperotto A, Cerno M, Fili C, Zaja F et al. Sclerodermatous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: incidence, predictors and outcome. Haematologica 2006; 91: 258\u2013261.","journal-title":"Haematologica"},{"key":"BFbmt2014210_CR10","doi-asserted-by":"publisher","first-page":"4250","DOI":"10.1182\/blood-2011-04-350249","volume":"118","author":"KJ Martires","year":"2011","unstructured":"Martires KJ, Baird K, Steinberg SM, Grkovic L, Joe GO, Williams KM et al. Sclerotic-type chronic GVHD of the skin: clinical risk factors, laboratory markers, and burden of disease. Blood 2011; 118: 4250\u20134257.","journal-title":"Blood"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2014210.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2014210","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2014210.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T18:12:39Z","timestamp":1648059159000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2014210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,29]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["BFbmt2014210"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2014.210","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,29]]},"assertion":[{"value":"29 September 2014","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}